Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

Eli Lilly CEO confirms oral obesity drug Phase 3 results expected in Q2 Eli Lillys CEO updates on drug trials amid mixed ...

Medical experts proposed a radical overhaul of how obesity is diagnosed, moving away from relying on body mass alone and ...

The recommendation signals a long-awaited shift from a single imperfect metric toward a more personalised diagnosis ...

An international and widely supported group of experts is pushing doctors to avoid the exclusive use of BMI to decide whether ...

Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...